ADMA Biologics Inc.

19.47
-0.76 (-3.76%)
At close: Apr 03, 2025, 3:59 PM
19.29
-0.92%
Pre-market: Apr 04, 2025, 04:47 AM EDT

Company Description

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.

It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.

The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin.

In addition, it operates source plasma collection facilities.

The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers.

ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

ADMA Biologics Inc.
ADMA Biologics Inc. logo
Country United States
IPO Date Oct 17, 2013
Industry Biotechnology
Sector Healthcare
Employees 685
CEO Adam S. Grossman

Contact Details

Address:
465 State Route 17
Ramsey, New Jersey
United States
Website https://www.admabiologics.com

Stock Details

Ticker Symbol ADMA
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001368514
CUSIP Number 000899104
ISIN Number US0008991046
Employer ID 56-2590442
SIC Code 2836

Key Executives

Name Position
Adam S. Grossman Co-Founder, President, Chief Executive Officer & Director
Brad Tade Chief Financial Officer & Treasurer
Kaitlin Kestenberg Chief Operating Officer & Senior Vice President of Compliance
Cindy Petersen Vice President of Human Resources
Dr. Jerrold B. Grossman D.P.S., Ph.D. Co-Founder & Vice Chairman of the Board
Drew Pantello Vice President of Marketing & Corporate Development
John Hafl Executive Director of Sales
Skyler Bloom Senior Director of Business Development & Corporate Strategy

Latest SEC Filings

Date Type Title
Apr 02, 2025 4 Filing
Mar 21, 2025 4 Filing
Mar 18, 2025 10-K Annual Report
Mar 10, 2025 4 Filing
Mar 10, 2025 4 Filing
Mar 03, 2025 NT 10-K Filing
Mar 03, 2025 8-K Current Report
Feb 27, 2025 4 Filing
Feb 27, 2025 4 Filing
Feb 27, 2025 4 Filing